Midday movers: Costco, Warner Bros. Discovery, Rivian and more

September 28, 2023 03:02 AM AEST | By Investing
 Midday movers: Costco, Warner Bros. Discovery, Rivian and more
Image source: Kalkine Media

Investing.com -- U.S. stocks erased early gains and turned lower, weighed by concerns about higher for longer interest rates and the rising potential for a government shutdown this weekend.

Here are some of the biggest U.S. stock movers today:

  • Costco (NASDAQ:COST) stock rose 1.5% as fourth quarter results beat expectations on both the top and bottom lines.

  • Warner Bros Discovery Inc (NASDAQ:WBD) shares rose 2.2% after Hollywood's writer's union ended its strike against major studios and streaming platforms, with a new tentative three year contract. Shares of Paramount Global Class B (NASDAQ:PARA) rose 1.9%.
  • Rivian (NASDAQ:RIVN) stock fell 0.4% after the EV manufacturer announced plans to use subscription models for monetizing various features in cars.

  • Amazon (NASDAQ:AMZN) stock fell 0.9% after the Federal Trade Commission filing a long-awaited antitrust lawsuit against the online retail giant.

  • Zions Bancorporation (NASDAQ:ZION) stock fell 0.9% after Morgan Stanley (NYSE:MS) downgraded the lender to ‘underweight’ from ‘equal weight’, citing an elevated valuation after gains of over 70% since May lows.

  • Mattel (NASDAQ:MAT) stock rose 3.7% after the toymaker posted a surprise profit in the second quarter and its sales exceeded market expectations, while the box office success of the "Barbie" movie is likely to help drive doll sales in the second half of the year.

  • Marriott International (NASDAQ:MAR) stock rose 0.7% after the hotel operator forecast two-year annualized global revenue per available room growth of 3% to 6% by 2025, expecting resilient international travel demand.

  • MillerKnoll (NASDAQ:MLKN) stock rose 28.7% after the upmarket furniture-maker raised its full-year profit outlook.

  • Cardiff Oncology (NASDAQ:CRDF) stock rose 4.3% after the biotechnology company announced favorable data from two cancer drug trials.

This article first appeared in Investing.com


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.


AU_advertise

Advertise your brand on Kalkine Media

Sponsored Articles


Investing Ideas

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.